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Background Peginterferon alfa-2a induces durable responses in some hepatitis B e antigen-
negative patients, but robust pretreatment predictors are not available to identify likely responders. 
In this study we aimed to develop genotype-specific baseline scoring systems to predict response.
Methods Data from 323 hepatitis B e antigen-negative peginterferon alfa-2a recipients from three 
studies were analyzed. Scoring systems were developed using generalized additive models and 
multiple logistic regression analysis. Response was defined as hepatitis B virus DNA <2000 IU/mL 
alone (virological response) or in combination with alanine aminotransferase normalization 
(combined response) 48 weeks post-treatment.
Results Points were assigned to genotype B/C patients for: age, alanine aminotransferase ratio, 
genotype B or C, and hepatitis B surface antigen level; and to genotype D patients for: age, hepatitis 
B surface antigen level and hepatitis B virus DNA level. Higher total scores (range 0-5 for B/C; 
0-3 for D) indicated a higher likelihood of response. Among genotype B/C patients with scores of 
0-1, 2 and ≥3, respectively, virological response rates were 16.7%, 25.8% and 70.2%, and combined 
response rates were 12.5%, 21.0% and 57.4%. Among genotype D patients with scores of 0-1, 2 and 
3, respectively, virological response rates were 10.1%, 28.0% and 50.0%, and combined response 
rates were 7.8%, 28.0% and 33.3%.
Conclusion Genotype-specific baseline scoring systems can identify hepatitis B e antigen-negative 
patients with low or high likelihood of achieving sustained responses to peginterferon alfa-2a.
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Abstract
Introduction
Chronic hepatitis B (CHB) is associated with serious 
complications, including liver failure, cirrhosis, and 
hepatocellular carcinoma, and is estimated to contribute to 
650,000 deaths each year [1]. Hepatitis B e antigen (HBeAg)-
negative CHB represents a late phase of infection characterized 
by persistent viral replication, progressive liver damage and 
cirrhosis [2,3]. The prevalence of HBeAg-negative CHB is 
increasing worldwide because of aging of populations [4,5]. 
Current guidelines recommend the use of nucleot(s)ide analogs 
(NAs) or conventional or pegylated interferon (PegIFN) alfa 
as first-line therapy for HBeAg-negative CHB [5,6]. NAs are 
highly effective at suppressing hepatitis B virus (HBV) DNA 
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replication and are well tolerated; however, relapse occurs 
frequently after withdrawal of therapy [5,6]. Hepatitis B 
surface antigen (HBsAg) levels decline very slowly during NA 
therapy [7]. Consequently, NA therapy must be continued for 
life to remain effective in the majority of patients [5], placing 
a burden both on the patients, who must adhere to the daily 
dosing regimen, and on healthcare systems, which must sustain 
potentially lifelong treatment programs.
In contrast to NAs, PegIFN alfa-2a induces virological 
responses that are durable after completion of treatment in 
approximately one-third of HBeAg-negative patients [8,9] and 
are sustained during long-term follow up [10,11]. The decline 
in HBsAg is more rapid during PegIFN than NA therapy [12], 
and PegIFN appears to be the driver of HBsAg decline and 
clearance when used in combination with tenofovir [13].
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However, treatment is often associated with side effects that 
may lead to discontinuation of therapy in some patients. The 
ability to identify patients most likely to respond to PegIFN alfa 
would be clinically useful, allowing clinicians to select patients 
most likely to respond to a finite course of such treatment, as 
well as those most likely to require long-term treatment with 
NAs.
The use of on-treatment factors, such as the decline in 
HBV DNA or HBsAg, to identify patients likely or unlikely 
to respond to PegIFN alfa is well established in clinical 
practice  [14]. Monitoring HBsAg and HBV DNA during 
PegIFN alfa-2a therapy can identify patients likely to achieve 
a post-treatment response [9,15-19]. Although the ability 
to identify potential responders during treatment is useful, 
it would be better to identify such patients before initiating 
treatment. Current guidelines recommend consideration of 
baseline factors in treatment decisions regarding HBeAg-
positive patients only [5]. Limited data suggest that baseline 
factors can identify HBeAg-negative patients likely to respond 
to PegIFN alfa-2a [8,10,20,21]; however, the use of baseline 
factors to predict response is not currently part of routine 
clinical practice, because individual factors have relatively low 
negative and positive predictive values for treatment response.
The objective of this analysis was to develop a baseline 
scoring system to estimate, prior to treatment, the likelihood of 
an HBeAg-negative patient achieving a durable off-treatment 
response after receiving PegIFN alfa-2a therapy.
Materials and methods
We conducted a pooled retrospective analysis of 
data from three studies of PegIFN alfa-2a (PEGASYS®, 
Roche, Basel, Switzerland) in HBeAg-negative patients: 
a large phase III randomized study (WV16241) [8]; a 
phase IV randomized study (PegBeLiver, ML18253, 
NCT01095835) [9]; and a nonrandomized study (PERSEAS, 
ML22016, NCT01283074)  [22]. Data from 323 HBeAg-
negative patients were included (192 from WV16241  [8], 
48 from PegBeLiver  [9] and 83 from PERSEAS [22]). All 
patients with HBV genotype  B/C infection were derived 
from WV16241 [8], while patients with genotype D infection 
were derived from all three studies [8,9,22]. Differences 
in response rates in the three studies were not statistically 
significant (P>0.05, Chi Square tests).
Selection criteria
Inclusion and exclusion criteria for these studies have been 
described previously [8,9,22]. Patients infected with HBV 
genotype  B, C, or D, assigned to 48  weeks’ treatment with 
PegIFN alfa-2a 180  µg/week (without/with lamivudine) and 
who had baseline quantitative HBsAg, HBV DNA and alanine 
aminotransferase (ALT) data, were included. Patients from 
WV16241 were included only if they had participated in a 
long-term follow-up study (WV16866).
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Outcome definitions
Two outcomes were used in the analyses, both determined at 
48 weeks post-treatment: HBV DNA <2000 IU/mL (virological 
response), and the combination of HBV DNA <2000  IU/mL 
plus normal ALT (combined response). Patients with missing 
HBV DNA or ALT values at 48  weeks post-treatment were 
considered non-responders.
Development of baseline prediction score
HBV genotype influences the response to IFN [5]; hence, 
separate scores were developed for patients infected with 
genotype  B or C (B/C) and those with genotype  D. The 
number of patients with genotype A infection was insufficient 
to develop a scoring system.
The baseline prediction scoring systems were developed 
following several steps. First, generalized additive models 
(GAMs) with the logit link were used to identify appropriate 
cutoffs via visual inspection for continuous predictors. This 
included a search for the most statistically significant cutoff 
for each continuous baseline factor using logistic regression 
analysis, which could be used to stratify patients into two 
subgroups corresponding to high and low response rates 
(virological response and combined response data were 
considered when defining cutoffs). Baseline factors included in 
these analyses were age, HBV DNA, HBsAg, ALT level and sex. 
Next, separate multiple  logistic regression (MLR) models were 
developed for patients infected with genotypes B/C and D, using 
a backward elimination process that considered only those 
factors (and cutoffs) associated with a response with a P-value 
of <0.2 in the univariate analysis. In the backward selection 
procedure, a P-value of 0.15 was used to select factors that 
would remain in the models, which allowed for the inclusion 
of factors with moderate predictive value. Internal validation 
methods were applied to assess the stability of the selected 
model, using bootstrap resampling methods [23]. A  variable 
was considered to be a reliable predictor if it was selected in at 
least 50% of 500 bootstrapped samples with replacement. The 
discrimination of the model was quantified by calculating the 
area under the receiver operating characteristics curve (ROC-
AUC: target ≥0.7); corresponding 95% confidence interval (CI) 
and the optimism-corrected ROC-AUCs were determined 
using the bootstrap samples. The Hosmer-Lemeshow test was 
applied to assess the goodness of fit of the final model (i.e., no 
P-value <0.05).
Factors that remained in the model of only one endpoint 
were added to the model for the other, to ensure that the 
models for both endpoints contained the same set of factors. 
To devise the scoring system for patients infected with HBV 
genotype B/C or D, predictive baseline characteristics retained 
in the MLR models were assigned points, taking into account 
the magnitude of the regression coefficients estimated in the 
models [24]: a value of 0 points was assigned to the reference 
category for each predictive factor; next, points were assigned 
according to the size of the regression coefficient, using 1 as the 
unit for 1 point with rounding to integer values.
Points assigned for individual characteristics were summed to 
arrive at a total score for each patient, with higher scores indicating 
a higher chance of achieving a response. Response rates by 
prediction scores were determined, including 95% CIs. Prediction 
characteristics (sensitivity, specificity, positive predictive value, 
negative predictive value [NPV]) and the positive likelihood ratio 
were determined for the two endpoints for both prediction scores.
An analysis of patients with genotype  B/C infection 
enrolled in China, Hong Kong and Taiwan is provided in the 
Supplementary Data.
Applicability of stopping rules
The applicability of the stopping rule recommended by the 
European Association for the Study of the Liver (no decline in 
HBsAg and <2-log10 decline in HBV DNA at treatment Week 
12) was evaluated after stratifying patients by baseline score.
Results
Patients
A total of 778 patients were assigned to treatment, of whom 323 
were included in the analysis of baseline characteristics. Reasons 
for exclusion from the analysis are shown in Supplementary 
Fig. 1. The study population comprised 157 patients with HBV 
genotype B/C infection, all of Asian ethnicity, and 166 patients with 
HBV genotype D infection, all of Caucasian ethnicity (Table 1). 
Baseline characteristics of patients from each study are shown in 
Supplementary Table 1. Among genotype B/C patients, the mean 
age was 38.9  years and 83.4% were male. Among genotype  D 
patients, the mean age was 43.7 years, and 70.5% were male. The 
prevalence of METAVIR Stage 4 fibrosis was 7.6% among patients 
with genotype B/C infection who had a pretreatment biopsy result 
and 2.6% among patients with genotype D infection.
Development of baseline prediction score
Graphic analysis and univariate logistic regression analysis 
to identify baseline predictive factors and appropriate cutoffs
The GAM plots show the relationships between continuous 
variables (age, ALT ratio, HBsAg level, and HBV DNA level) and 
treatment response in patients infected with HBV genotype B/C 
(Supplementary Fig. 2A-H) and D (Supplementary Fig. 3A-H). 
Based on these analyses and the search for optimal cutoffs using 
univariate logistic regression (ULR) analysis, the following cutoffs 
were considered for further analysis in patients infected with 
HBV genotype B/C: age ≤30, >30-45 and >45 years; ALT ratio <5 
and ≥5 × upper limit of normal (ULN); HBsAg level <1250 and 
≥1250 IU/mL; and in patients infected with HBV genotype D: 
age ≤45 and >45 years; HBsAg <2500 and ≥2500 IU/mL; HBV 
DNA <35,000 and ≥35,000 IU/mL. Inspection of the GAM plots 
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Figure 1 Genotype B or C patients (A, B) and genotype D patients (C, D) with a virological response (HBV DNA <2000 IU/mL) and a combined 
response (HBV DNA <2000 IU/mL and normal ALT) at 48 weeks post-treatment by baseline characteristic. Only factors included in the scoring 
systems are shown
ALT, alanine aminotransferase; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus
A B
C D
showed that the relationship between the response variables 
and HBV DNA level in genotype B/C patients (Supplementary 
Fig.  2A-H), and ALT ratio in genotype  D patients was not 
monotonic (Supplementary Fig.  3A-H); therefore, no cutoffs 
were selected for further analyses.
Among the 157 patients with HBV genotype B/C infection, 
57 individuals (36.3%) had a virological response and 46 
individuals (29.3%) achieved a combined response at 48 weeks 
post-treatment. Among the 166 patients with HBV genotype D 
infection, 26  individuals (15.7%) achieved a virological 
response and 21 individuals (12.7%) achieved a combined 
response at 48 weeks post-treatment.
Response rates by baseline characteristics included in the 
ULR analyses are shown by HBV genotype (B/C and D) and 
type of response in Fig. 1A-D. The ULR analyses of response 
rates according to baseline characteristics are shown in Table 2 
for patients infected with HBV genotype B/C and in Table 3 for 
patients infected with HBV genotype D.
Multivariate logistic regression 
For patients infected with HBV genotype B/C, four baseline 
factors (age, ALT ratio, HBV genotype and HBsAg level) identified 
by ULR analysis as being predictive for responses at 48  weeks 
post-treatment (P<0.2) were included in the MLR model selection 
procedure (backward elimination with P<0.15). For virological 
response, age, HBV genotype and HBsAg remained significant 
after the backward selection process (all P<0.01, Table 2), while age, 
ALT ratio and genotype were retained after the selection process 
for a combined response (P<0.1, Table 2). The covariates of the 
final MLR models were selected in ≥60% of the bootstrap samples, 
which shows the stability of the models, while the ROC-AUCs 
and Hosmer-Lemeshow test indicate sufficient discrimination 
and goodness of fit (Table 2, Supplementary Figs. 4,5). When all 
four factors were included in the MLR models for both endpoints, 
the regression coefficients and odds ratios of the significant factors 
were very similar (data not shown).
For patients infected with HBV genotype  D, three baseline 
factors were retained in the final model for virological response 
(Table 3): age, HBsAg level and HBV DNA level (all P<0.1); and two 
factors were retained in the final model for a combined response 
(Table 3): age and HBsAg level (all P<0.01). Again, the covariates 
of the final MLR models were selected in ≥60% of the bootstrap 
samples showing the model’s stability, and the ROC-AUCs and 
Hosmer-Lemeshow test indicate sufficient discrimination and 
goodness of fit (Table 3, Supplementary Figs. 6,7). When all three 
factors were included in the MLR model for a combined response, 
the regression coefficients and odds ratios of the significant factors 
were very similar (data not shown).
Predictors of PegIFN response in HBeAg-negative CHB  5
Annals of Gastroenterology 31
To formulate the scoring systems, baseline factors were 
ranked according to the regression coefficients, and points 
were assigned according to the size of the regression coefficient 
(Tables 2 and 3) using 1 as the unit for 1 point. For example, 
the regression coefficient for genotype (C vs. B), for virological 
response (1.1725), and for combined response (0.9366) divided 
by 1 and rounded to an integer value results in an assigned value 
of 1 point. In genotype B/C patients, 1 point was assigned for 
HBsAg <1250 IU/mL and for ALT ≥5 × ULN, although these 
factors were only significant for one of the two post-treatment 
response variables. In genotype  D patients, the final MLR 
model for virological response was used to devise the scoring 
system. The resulting scoring systems used to determine an 
individual patient’s probability of achieving a post-treatment 
response with PegIFN alfa-2a (Table 4) have a maximum score 
of 5 for genotype C, 4 for genotype B, and 3 for genotype D.
Among patients infected with HBV genotype  B or C, the 
distribution of prediction scores in the patient population (N=157) 
was: 0 points: 5.1% (n=8); 1 point: 25.5% (n=40); 2 points: 39.5% 
(n=62); 3 points: 21.7% (n=34); 4 points: 7.6% (n=12); and 5 
points: 0.6% (n=1). Predictive scores were grouped as follows: 0-1 
(n=48), 2 (n=62) and ≥3 (n=47) points to form groups of patients 
with a low, moderate and high chance of response.
Among patients infected with HBV genotype D, the distribution 
of prediction scores in the patient population (N=166) was: 0 points: 
27.1% (n=45); 1 point: 50.6% (n=84); 2 points: 15.1% (n=25); and 3 
points: 7.2% (n=12). Predictive scores were grouped as follows: 0-1 
(n=129), 2 (n=25) and 3 (n=12) points to form groups of patients 
with a low, moderate and high chance of response.
Response rates according to predictive score
Response rates at 48  weeks post-treatment increased 
with increasing baseline score in patients infected with HBV 
genotypes B/C or D. Among 47  patients infected with HBV 
Table 1 Baseline characteristics
Characteristic Total (N=323) Genotype B/C (n=157) Genotype D (n=166)
Age, years, mean [±SD] 41.3 [11.0] 38.9 [11.1] 43.7 [10.4]
Sex, male, n (%) 248 (76.8) 131 (83.4) 117 (70.5)
Race, n (%)
Caucasian 166 (51.4) 0 166 (100)
Asian 157 (48.6) 157 (100) 0
Country, n (%)
China/Hong Kong/Taiwan 135 (41.8) 135 (86.0) 0
Thailand 17 (5.3) 17 (10.8) 0
Greece 86 (26.6) 0 86 (51.8)
Italy 63 (19.5) 0 63 (38 .0)
Other 22 (6.8%) 5 (3.2)a 17 (10.2)b
ALT ratio, × ULN, mean [±SD] 2.84 [2.37] 3.12 [2.54] 2.57 [2.17]
Patients who underwent biopsy, n (%) 272 (84.2) 157 (100) 115 (69.2)
METAVIR score, n (%)c
0 27 (9.9) 19 (12.1) 8 (7.0)
1 106 (39.0) 47 (29.9) 59 (51.3)
2 84 (30.9) 51 (32.5) 33 (28.7)
3 40 (14.7) 28 (17.8) 12 (10.4)
4 15 (5.5) 12 (7.6) 3 (2.6)
HBV genotype, n (%)
B 64 (19.8) 64 (40.8) 0
C 93 (28.8) 93 (59.2) 0
D 166 (51.4) 0 166 (100)
HBsAg, log10 IU/mL, mean [±SD] 3.46 [0.57] 3.27 [0.58] 3.64 [0.51]
HBV DNA, log10 IU/mL, mean [±SD] 6.19 [1.79] 6.66 [2.06] 5.75 [1.35]
aFrance, Germany, New Zealand; bGermany, Poland, Spain, Turkey; cLiver biopsies were staged using the METAVIR scoring system in the study by Marcellin 
et al. and using the Ishak scoring system in PERSEAS and PegBeLiver. Assigned fibrosis stages in PERSEAS and PegBeLiver were converted to METAVIR 
scores by using the method of Shiha and Zalata [27]
ALT, alanine aminotransferase; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; SD, standard deviation; ULN, upper limit of normal
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genotype B/C and scores ≥3, 33 individuals (70.2%) achieved 
a virological response and 27 individuals (57.4%) achieved 
a combined response and among 48  patients with scores of 
0-1, eight individuals (16.7%) achieved a virological response 
and six individuals (12.5%) achieved a combined response 
(Fig.  2A). The performance characteristics of the two scores 
are provided in Supplementary Table 2 and the response rates 
by prediction score are shown in Supplementary Table  3 for 
genotypes B and C separately. The results are consistent across 
genotypes B and C; for example, for patients with genotype B or 
C the combined response rate is ≥50% in those with prediction 
scores ≥3 and ≤25% for those with scores ≤2. Among 
genotype B patients with a baseline score of 0-1 the NPV for 
a combined response was 90.9% (30 of 33  patients did not 
achieve a combined response); and among genotype C patients 
with a baseline score of 1, the lowest possible for genotype C, 
the NPV for a combined response was 80.0% (12 of 15 patients 
did not achieve a combined response).
Post-treatment response rates were lower in patients with 
HBV genotype  D infection, and the proportion of patients 
with a favorable baseline score (3 points) was low. Among 
12  patients with a baseline score of 3, six individuals (50%) 
achieved a virological response and four individuals (33.3%) 
achieved a combined response, and among 129 patients with 
a baseline score of 0-1, 13 individuals (10.1%) achieved a 
virological response and 10 individuals (7.8%) achieved a 
combined response (Fig.  2B). Among genotype  D patients 
with a baseline score of 0-1, the NPV for a combined response 
was 92.2% (119 of 129  patients did not achieve a response); 
however, for patients with a score of 0, the NPV was 100% 
(45/45), and for those patients with a score of 1, the NPV was 
88.1% (74/84).
HBsAg clearance rates also increased with increasing 
baseline score (Fig. 2C).
Applicability of on-treatment stopping rule by predictive 
score
When patients were categorized by baseline score, there 
were no statistically significant differences in the number of 
individuals (genotype  B/C or D) who met the criterion for 
discontinuing therapy at Week 12 (Supplementary Table 4).
Discussion
This analysis shows that HBeAg-negative patients with 
a high or low chance of achieving a post-treatment response 
to PegIFN alfa-2a can be identified with genotype-specific 
baseline scoring systems. The systems employ readily 
available demographic and laboratory data and could 
easily be incorporated into routine patient visits to assist 
Figure 2 Virological and combined response rates at 48 weeks post-treatment by baseline prediction score in patients infected with HBV genotypes 
B or C (A) and D (B), and HBsAg clearance rates in patients infected with HBV genotypes B or C, and D (C). Error bars are 95% confidence intervals
ALT, alanine aminotransferase; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus
A B
C
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clinicians discussing treatment options with patients. With 
the prediction scores developed here, points are assigned for 
age, ALT ratio, HBV genotype and HBsAg level for patients 
with genotype  B/C infection, and for age, HBsAg and HBV 
DNA levels for patients with genotype D infection. Individual 
patient scores range from 0 to 5 for genotype B/C patients and 
from 0 to 3 for genotype D patients. Higher scores indicate a 
greater likelihood of achieving a virological response (HBV 
DNA <2000  IU/mL) and a combined response (HBV DNA 
<2000 IU/mL plus normal ALT) 48 weeks after completing a 
standard 48-week course of treatment with PegIFN alfa-2a. 
Among genotype  B/C patients, patients with scores ≥3 had 
Table 2 Univariate and multiple logistic regression analysis of factors associated with virological response (HBV DNA <2000 IU/mL) and 
combined response (HBV DNA <2000 IU/mL and normal ALT) in patients infected with HBV genotype B or C
Univariate logistic regression Final multiple logistic regression model Selected in 
bootstrap 
models
Baseline 
characteristic
Regression 
coefficient
Odds ratio 
(95%CI)
P-valuea Regression 
coefficient
Odds ratio  
(95%CI)
P-valuea
Virological response (HBV DNA <2000 IU/mL) at 48 weeks post-treatment
Sex, male vs. female 0.2960 1.344  
(0.544, 3.323)
0.5214 b
Genotype C vs. B 0.8609 2.365  
(1.177, 4.755)
0.0157 1.1725 3.230  
(1.460, 7.149)
0.0038 94%
Age, years
≤30 vs. >45 1.9135 6.777  
(2.447, 18.771)
0.0002 2.4469 11.552  
(3.680, 36.267)
<0.0001
>99%
31-45 vs. >45 0.7049 2.024  
(0.820, 4.996)
0.1264 0.9584 2.607  
(0.985, 6.901)
0.0536
ALT ratio ≥5 vs. <5 
× ULN
0.7689 2.157  
(0.883, 5.271)
0.0916 36%
HBsAg <1250 vs. 
≥1250 IU/mL
0.8517 2.344  
(1.173, 4.681)
0.0158 1.2506 3.493  
(1.571, 7.766)
0.0022 97%
AUC = 0.761, 95% CI: 0.682-0.840 
Optimism-corrected AUC = 0.737, 
Hosmer-Lemeshow P-value = 0.91
Combined response (HBV DNA <2000 IU/mL and normal ALT) at 48 weeks post-treatment 
Sex, male vs. female 0.1403 1.151  
(0.448, 2.957)
0.7708 b
Genotype C vs. B 0.7690 2.158  
(1.027, 4.534)
0.0423 0.9366 2.551  
(1.131, 5.755)
0.0240 84%
Age, years
≤30–45 vs. >45 2.3871 10.882  
(3.221, 36.767)
0.0001 2.4158 11.199  
(3.169, 39.573)
0.0002
>99%
31–45 vs. >45 1.2726 3.570  
(1.139, 11.195)
0.0291 1.2392 3.453  
(1.082, 11.016)
0.0363
ALT ratio ≥ 5 vs. <5 
× ULN
1.1658 3.209  
(1.297, 7.939)
0.0117 0.8729 2.394  
(0.878, 6.527)
0.0880 60%
HBsAg <1250 vs. 
≥1250 IU/mL
0.0496 1.051  
(0.504, 2.192)
0.8947 b
AUC  =  0.758, 95% CI: 0.676-0.840 
Optimism-corrected AUC = 0.727, 
Hosmer-Lemeshow P-value = 0.75
aWald chi-square test for each regression coefficient; bP>0.25 in the univariate analysis and thus not considered in the multiple logistic regression analysis and 
the bootstrap samples
ALT, alanine aminotransferase; AUC, area under the curve; CI, confidence interval; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; ULN, upper limit of 
normal
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a high chance (>50%), with a score of 2, a moderate chance 
(~25%), and with scores of 0 or 1, a low chance (~15%) of 
achieving a post-treatment response.
A smaller proportion of patients with the more-
challenging-to-treat genotype D infection were identified as 
having a high chance of achieving a post-treatment response. 
Moreover, the response rates were lower in these individuals 
than in those with genotype  B/C infection. Although 
genotype D patients are less likely to be suitable candidates for 
PegIFN alfa-2a, the tool may be most useful in this difficult-
to-treat group, because it identifies those few patients who 
may benefit from PegIFN alfa-2a. In the PegBeLiver study, a 
total of 12% of patients (6/51) randomized to a standard 48-
week course of PegIFN alfa-2a therapy achieved a combined 
response (which was defined as HBV DNA <3400 IU/mL and 
normal ALT levels 48 weeks post-treatment); none of these 
cleared HBsAg [9]. In the present analysis, few patients were 
identified as having a good chance of a response (baseline 
score of 3); however, one-third of patients with a baseline 
score of 3 achieved a combined response at 48 weeks post-
treatment. Thus, the results imply that, although overall 
response rates to PegIFN alfa-2a are quite low in patients 
with genotype D infection, it is possible to identify the few 
patients who are most likely to respond on the basis of their 
baseline characteristics.
The utility of the scoring systems may vary according to 
genotype. For patients with genotype B infection, who usually 
have the highest response rates, the score may be most useful 
to confirm the suitability of patients for peginterferon alfa-2a, 
whereas, for genotype C and particularly D infection, response 
rates are generally lower and the score may be most appropriate 
for excluding patients who may have been considered for 
peginterferon alfa-2a treatment.
No decline in HBsAg and <2-log10 decline in HBV DNA 
by Week 12 of treatment with PegIFN alfa (PARC rule) is 
recommended as a stopping rule because few patients that meet 
Table 3 Univariate and multiple logistic regression analysis of factors associated with virological response (HBV DNA <2000 IU/mL) and 
combined response (HBV DNA <2000 IU/mL and normal ALT) in patients infected with HBV genotype D
Univariate logistic regression Final multiple logistic regression model Selected in 
bootstrap 
models
Baseline characteristic Regression 
coefficient
Odds ratio  
(95% CI)
P-valuea Regression 
coefficient
Odds ratio  
(95%CI)
P-valuea
Virological response (HBV DNA <2000 IU/mL) at 48 weeks post-treatment
Sex, female vs. male 0.0706 1.073  
(0.432, 2.663)
0.8790 b
Age ≤45 vs. >45 years 1.0608 2.889  
(1.094, 7.627)
0.0322 0.9997 2.717  
(0.976, 7.564)
0.0556 67%
HBsAg <2500 vs. 
≥2500 IU/mL
1.1214 3.069  
(1.268, 7.430)
0.0129 0.9080 2.479  
(0.924, 6.656)
0.0715 61%
HBV DNA <35,000 vs. 
≥35,000 IU/mL
1.5756 4.833  
(1.994, 11.718)
0.0005 1.2174 3.379  
(1.300, 8.780)
0.0125 82%
AUC = 0.763, 95% CI: 0.672-0.854,  
Optimism-corrected AUC = 0.721,  
Hosmer-Lemeshow P-value = 0.32
Combined response (HBV DNA <2000 IU/mL and normal ALT) at 48 weeks post-treatment
Sex, female vs. male 0.4453 1.561  
(0.602, 4.044)
0.3592 b
Age ≤45 vs. >45 years 1.6675 5.299 
(1.495, 18.774)
0.0098 1.8515 6.369 
(1.733, 23.416)
0.0053 90%
HBsAg <2500 vs. 
≥2500 IU/mL
1.0987 3.000 
(1.154, 7.798)
0.0242 1.3382 3.812 
(1.379, 10.537)
0.0099 71%
HBV DNA <35,000 vs. 
≥35,000 IU/mL
1.1423 3.134 
(1.203, 8.166)
0.0194 44%
AUC = 0.730, 95% CI: 0.631–0.829
Optimism-corrected AUC = 0.691,
Hosmer-Lemeshow P-value = 0.92
aWald chi-square test for each regression coefficient;  bP>0.25 in the univariate analysis and thus not considered in the multiple logistic regression analysis and 
the bootstrap samples
ALT, alanine aminotransferase; AUC, area under the curve; CI, confidence interval; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus
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these criteria have achieved a response in clinical trials [25,26]. 
In this analysis we were not able to correlate the baseline 
prediction scoring system with the PARC rule.
Strengths of the present analysis include the development 
of separate scoring systems for patients with genotype  B/C 
and D infection and the use of 48-week post-treatment data 
in the outcome definition. The ability to identify patients likely 
to develop off-treatment responses with PegIFN alfa-2a is 
desirable because it would allow clinicians to target treatment 
to those patients most likely to respond, while minimizing 
the number of likely non responders who are exposed to the 
potential adverse events of treatment.
Limitations include the retrospective nature of the study 
and the pooled analysis, the relatively small number of 
patients (especially genotype  D patients), the lack of a score 
for genotype A patients and the lack of an external validation 
cohort. The lack of ethnic diversity within each genotype group 
(i.e., all genotype B/C patients were Asian and all genotype D 
patients were Caucasian) and the lack of comprehensive 
information on liver disease severity are also limitations. HBV 
genotyping may not be reimbursed in some countries, so the 
need for HBV genotype may be seen as a limitation; however, 
the subanalysis in Asian patients shows that the score can still 
be used when this factor is not available. The scoring system 
must be prospectively validated before it can be recommended 
for use in routine clinical practice, and it would be reassuring 
to confirm whether patients identified by these scoring systems 
also have a high probability of experiencing HBsAg clearance 
or seroconversion. Future analyses should also attempt to 
evaluate the baseline scoring system prospectively, while 
applying on-treatment stopping rules. Application of these 
prediction scores requires that clinicians have knowledge of 
the HBV genotype and quantitative HBsAg levels. These tests 
may not be available in all practice settings, which would limit 
the utility of this tool.
In conclusion, the proposed baseline scoring systems for 
HBeAg-negative patients infected with HBV genotype  B/C 
and D use readily available baseline characteristics and enable 
physicians to identify patients with a low, moderate, or high 
chance of achieving a post-treatment response to PegIFN alfa-
2a. The benefit/risk ratio should be carefully considered before 
initiating treatment in patients with scores of 0-1, given that 
these indicate a low chance of success.
Table 4 Scoring system for predictive baseline characteristics in 
patients infected with HBV genotypes B or C, or D
Characteristic Score
HBV genotype B or C
Age, years
>45 0
>30-45 1
≤30 2
ALT ratio, × ULN
<5 0
≥5 1
HBV genotype
B 0
C 1
HBsAg, IU/mL
≥1250 0
<1250 1
HBV genotype D
Age, years
>45 0
≤45 1
HBsAg, IU/mL
≥2500 0
<2500 1
HBV DNA, IU/mL
≥35,000 0
<35,000 1
ALT, alanine aminotransferase; HBsAg, hepatitis B surface antigen; HBV, 
hepatitis B virus; ULN, upper limit of normal
Summary Box
What is already known:
•	 Peginterferon	alfa-2a	induces	durable	responses	in	
approximately one-third of hepatitis B e antigen-
negative patients with chronic hepatitis B
•	 Baseline	disease	factors,	such	as	higher	hepatitis	B	
virus DNA and hepatitis B surface antigen levels, 
have been associated with a reduced likelihood of 
response
•	 Criteria	 to	 identify	 specific	 patients	 likely	 or	
unlikely to respond to peginterferon alfa-2a would 
permit targeting of resources and sparing of 
treatment for patients unlikely to respond 
What the new findings are:
•	 For	 patients	 with	 genotype  B	 or	 C	 disease,	 a	
baseline scoring system from 0 to 5 was developed 
based on age, genotype, alanine aminotransferase 
ratio and HBsAg level
•	 Only	16.7%	of	genotype B	or	C	patients	with	scores	
of 0 or 1 achieved a virological response, while 
70.2% of those with scores of 3-5 responded
•	 For	 patients	 with	 genotype  D	 disease,	 a	 scoring	
system from 0 to 3 based on age, hepatitis B surface 
antigen level and hepatitis B virus DNA level was 
predictive of response
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Application of the scoring system in Asian patients with HBV genotype B or C infection
Among the 157 patients with HBV genotype B or C infection, 135 individuals (86.0%) were enrolled in centers in China, Hong Kong, or 
Taiwan. The prediction score for genotype B/C was applied after removing the point assigned for genotype C. This was done because HBV 
genotype is rarely determined in patients with chronic hepatitis B in this region. The distribution of scores changed markedly after the removal 
of one point assigned for genotype in all patients with genotype C infection. Thus, among the 135 Chinese patients, prediction scores were 
distributed as follows: 0 points: 12.6% (n=17); 1 point: 39.3% (n=53); 2 points: 34.8% (n=47); 3 points: 12.6% (n=17); and 4 points: 0.7% (n=1). 
Predictive scores were grouped as follows: 0-1 (n=70), 2 (n=47), and ≥3 (n=18) points to form groups of patients with a low, moderate, and high 
chance of response.
Among Chinese patients infected with HBV genotype B/C, the percentage of patients with a virological response at 48 weeks post-treatment 
increased with increased score from 22.9% (scores 0-1), to 44.7% (score 2), to 83.3% (scores ≥3), while the corresponding combined response 
rates were 15.7%, 40.4%, and 66.7% (Supplementary Fig. 8). This indicates that the modified score might be applicable in Chinese patients with 
missing genotype determination, where almost all patients have genotype B or C. 
G
H
Supplementary Figure 3 GAM analysis in patients infected with HBV genotype D: Virological response (HBV DNA <2000 IU/mL) 48 weeks post-treatment 
by (A) age, (B) ALT ratio, (C) HBsAg and (D) HBV DNA; Combined response (HBV DNA <2000 IU/mL and normal ALT) 48 weeks post-treatment by (E) age, 
(F) ALT ratio, (G) HBsAg, and (H) HBV DNA
ALT, alanine aminotransferase; BL, baseline; DF, degree of freedom; GAM, generalized additive model; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; trt, 
treatment; ULN, upper limit of normal 
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Supplementary Figure 4 ROC curves for HBV DNA <2000 IU/mL at 48 weeks post-treatment in genotype B/C patients for final model and for each individual 
factor in the model
HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; ROC, receiver operating characteristics
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Supplementary Figure 5 ROC curves for combined response at 48 weeks post-treatment in genotype B/C patients for final model and for each individual factor 
in the model
ALT, alanine aminotransferase; HBV, hepatitis B virus; ROC, receiver operating characteristics
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Supplementary Figure 6 ROC curves for HBV DNA <2000 IU/mL at 48 weeks post-treatment in genotype D patients for final model and for each individual 
factor in the model
HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; ROC, receiver operating characteristics
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Supplementary Figure 7 ROC curves for combined response at 48 weeks post-treatment in genotype D patients for final model and for each individual factor in 
the model
HBsAg, hepatitis B surface antigen; ROC, receiver operating characteristics
Patients enrolled in centers in China, Hong Kong and Taiwan with genotype B or C infection (n=135)
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Supplementary Figure 8 Response rates at 48 weeks post-treatment by baseline prediction score in patients enrolled in centers in China, Hong Kong, or Taiwan 
(N=135) infected with HBV genotype B or C (Error bars are 95% confidence intervals)
Supplementary Table 1 Baseline characteristics of patients in the analysis according to original study 
Characteristic WV16241 (n=182) ML18253  (PegBeLiver) (n=48) ML22016 (PERSEAS)(n=83)
Age, years, mean [±SD]
Sex, male, n (%) 158 (82.3) 31 (64.6) 59 (71.18)
Race, n (%)
Caucasian 35 (18.2) 48 (100) 83 (100)
Asian 157 (81.8) 0 0
ALT ratio, x ULN, mean±SD 3.00±2.60 2.91±2.6 2.42±1.62
HBsAg, log10 IU/mL, mean±SD 3.35±0.57 3.77±0.42 3.53±0.59
HBV DNA, log10 IU/mL, mean±SD 6.54±1.97 6.22±1.22 5.36±1.31
Supplementary Table 2 Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and positive likelihood ratio for 
the two prediction scores for genotype B/C and D
Prediction score True False Sensitivity  (%) Specificity  (%) PPV (%) NPV (%) Positive likelihood ratio
Positive Negative Positive Negative
Genotype B or C patients
Combined response (HBV DNA<2000 IU/mL and normal ALT) at 48 weeks post‑treatment
≥1 45 7 104 1 97.8 6.3 30.2 87.5 1.04
≥2 40 42 69 6 87.0 37.8 36.7 87.5 1.40
≥3 27 91 20 19 58.7 82.0 57.4 82.7 3.26
≥4 9 107 4 37 19.6 96.4 69.2 74.3 5.43
≥5 1 111 0 45 2.2 100 100 71.2 NA
Virological response (HBV DNA<2000 IU/mL) at 48 weeks post‑treatment
≥1 56 7 93 1 98.2 7.0 37.6 87.5 1.06
≥2 49 40 60 8 86.0 40.0 45.0 83.3 1.43
≥3 33 86 14 24 57.9 86.0 70.2 78.2 4.14
≥4 11 98 2 46 19.3 98.0 84.6 68.1 9.65
≥5 1 100 0 56 1.8 100 100 64.1 NA
Genotype D patients
Combined response (HBV DNA<2000 IU/mL and normal ALT) at 48 weeks post‑treatment
≥1 21 45 100 0 100 31.0 17.4 100 1.45
≥2 11 119 26 10 52.4 82.1 29.7 92.2 2.92
≥3 4 137 8 17 19.0 94.5 33.3 89.0 3.45
Virological response (HBV DNA<2000 IU/mL) at 48 weeks post‑treatment
≥1 25 44 96 1 96.2 31.4 20.7 97.8 1.40
≥2 13 116 24 13 50.0 82.9 35.1 89.9 2.92
≥3 6 134 6 20 23.1 95.7 50.0 87.0 5.39
Sensitivity=100 x true positive/(true positive+false negative); Specificity=100 x true negative/(true negative+false positive); PPV=100 x true positive/
(true positive+false positive); NPV=100 x true negative/(true negative+false negative); Positive likelihood ratio=Sensitivity/(100 – Specificity) 
ALT, alanine aminotransferase; HBV, hepatitis B virus
Supplementary Tables
Supplementary Table 3 Response rates by prediction score in genotype B or C patients
Responder
Prediction score N n %
Genotype B patients
Combined response (HBV DNA<2000 IU/mL and normal ALT) at 48 weeks post‑treatment
0-1 33 3 9.1
2 24 6 25.0
3 7 4 57.1
Total 64 13 20.3
Virological response (HBV DNA<2000 IU/mL) at 48 weeks post‑treatment
0-1 33 5 15.2
2 24 6 25.0
3 7 5 71.4
Total 64 16 25.0
Genotype C patients
Combined response (HBV DNA<2000 IU/mL and normal ALT) at 48 weeks post‑treatment
0-1 15 3 20.0
2 38 7 18.4
3 27 14 51.9
≥4 13 9 69.2
Total 93 33 35.5
Virological response (HBV DNA<2000 IU/mL) at 48 weeks post‑treatment
0-1 15 3 20.0
2 38 10 26.3
3 27 17 63.0
≥4 13 11 84.6
Total 93 41 44.1
ALT, alanine aminotransferase; HBV, hepatitis B virus
Supplementary Table 4 Baseline prediction score by PARC rule statusa
PARC rule 
status
Baseline prediction score Total
0 1 2 3 4 5
Genotype B or C (n=157)
Fulfilled 0/5 4/19 3/39 0/17 1/6 0/1 8/87
Not fulfilled 5/5 15/19 36/39 17/17 5/6 1/1 79/87
Missing 3 21 23 17 6 0 70
Genotype D (n=166)
Fulfilled 8/38 9/66 2/20 2/7 NA NA 21/131
Not fulfilled 30/38 57/66 18/20 5/7 NA NA 110/131
Missing 7 18 5 5 NA NA 35
aPARC rule fulfilled=no decline in HBsAg and<2-log10 decline in HBV DNA from baseline to Week 12 of treatment
Pearson Chi-Square Test for association between baseline prediction score and PARC rule status: P=0.4886 for HBV genotype B or C and P=0.4121 for HBV 
genotype D
HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; NA, not applicable 
